2011 Biotech Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2011 Biotech Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Chris08	1/2/2012 4:25:34 PM
	Read Replies (3) of 400

I also learned quite a bit from an experience with Scios. When it appeared that Natrecor was going to be a blockbuster drug I built up a large position (for me) in Scios. I was taken in by the euphoria about the drug's future, from people who seemed to know a lot about it. So then, when Johnson and Johnson, bought out Scios I was furious, thinking that although the buyout had doubled my money, I had been deprived of vast future riches. Then Lady Luck came again to my rescue since it turned out J&J had bought a lemon, a drug that didn't do much and caused J&J a great deal of trouble. I was lucky again in a different way, saved from a big loss by J&J's big mistake. This brings me to VRUS. I bought some cheap, with no idea that it had a "winning" drug in the works, and when it went up, did not this time buy any more. Now Gilead has bought it out at a big premium, so, did I miss the boat? Or has Gilead made a mistake like J&J? The VRUS drug has not even been approved yet. I will be interested in how it all plays out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next